About the UroLift® System
The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years or older.
The UroLift® implants, designed to be permanent, delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue.1 The UroLift® System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.2 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*3-5 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.6 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Consult IFU for details of adverse effects.
The Prostatic Urethral Lift (PUL) procedure (using the UroLift® System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 400,000 men have been treated with the UroLift® System in select markets worldwide.7
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers.
Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anaesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift® System, and Weck® — trusted brands united by a common sense of purpose.
Sales Terms and Conditions
Sign Up for Updates on the UroLift® System
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift®, and Weck, are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2022 Teleflex Incorporated. All rights reserved.
Shore, Can J Urol 2014
Rukstalis, Prostate Cancer and Prostatic Dis 2018
Roehrborn, Can J Urol 2017
AUA BPH Guidelines 2003, 2020
McVary, J Sex Med 2016
Roehrborn, J Urology 2013
Management estimate based on product sales and average units per procedure
Healthcare Professional Confirmation
The information on the page you are about to enter is intended for Healthcare Professionals only.
By clicking the box below, you confirm that you are a Healthcare Professional.